Managing cardiovascular disease in Aboriginal and Torres

Strait islander people
The hope is certainly that use of a polypill formulation will improve adherence and reduce costs.
Combination analgesics in adults
Editor, -Thank you to Dr Murnion for the excellent review of combination analgesics (Aust Prescr 2010;33:113-5).
My understanding of the efficacy of codeine is that it is predominantly a prodrug and that the major analgesic effects derive through the actions of two of its major metabolites, codeine-6-glucuronide and morphine.
Under normal circumstances, most of the codeine is metabolised to codeine-6-glucuronide, with perhaps 10% appearing as morphine. The latter is produced through the action of cytochrome P450 2D6. It has been noted that a small proportion of the population have little CYP2D6 and receive less analgesia than expected. A similar effect is noted in those taking drugs such as fluoxetine which inhibit CYP2D6.
The converse is true for those hyper-metabolisers who have multiple copies of CYP2D6 or who take drugs such as dexamethasone which induce the enzyme.
Given the comments by Dr Murnion regarding the usefulness of paracetamol or a non-steroidal anti-inflammatory drug in conjunction with morphine, could she please comment on the possibility of better prescribing codeine (in combination or otherwise) based on the patient's CYP2D6 status.
Peter Bowron Senior hospital scientist Toxicology Unit -PaLMS North Ryde, NSW
Dr Bridin Murnion, the author of the article, comments:
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Hypertension, ACe inhibitors and angioedema
In the review about drug treatment of elevated blood pressure (Aust Prescr 2010;33:108-12), angioedema is not mentioned as a comorbid condition. I believe it would be helpful to do so.
Angioedema occurring with ACE inhibitors was first reported in 1980, 1 and may account for 40% of angioedema presentations to hospital. 2 onset may be delayed. 3 Epidemiological studies have confirmed a significant excess exposure to ACE inhibitors in patients with angioedema with an estimated attributable risk of 80% (CI* 51-92). 3 An incidence of 0.68% over six months has been reported, so annual incidence may be greater than 1%. 4 Rates in people of African origin are even higher, at 1.62% over six months, so may be over 3% annually. 4 This case emphasises the need for taking a complete drug history in patients. We specifically ask patients if they have used selective alpha 1 adrenergic antagonists, and put a stamp on the front of the history to ensure this is not overlooked if the patient requires cataract surgery in the future.
Given that tamsulosin is prescribed by surgeons in another discipline it is important that urologists or other doctors prescribing this medication in older patients emphasise the risk it poses in cataract surgery. The potential for adverse effects from medical therapy needs to be considered in every patient.
I have seen several patients on topical beta blockade for glaucoma develop such significant bradycardias that they have been considered for cardiac pacing before their drug history was properly checked. We need to be alert to the possibilities at all times to reduce the risk of harm to our patients.
Trevor Hodson
Consultant ophthalmologist Mount Gambier, SA
